Abstract:Meningiomas develop from meningothelial cells and approximately account for more than 30 percent of central nervous system (CNS) tumors. They can occur anywhere in the dura, most often intracranially and at dural reflection sites. Half of the cases are usually at parasagittal/falcine and convexity locations; other common sites are sphenoid ridge, suprasellar, posterior fossa, and olfactory groove. The female-to-male ratio is approximately 2 or 3-1, and the median age at diagnosis is 65 years. Meningiomas are generally extremely slow-growing tumors; many are asymptomatic or paucisymptomatic at diagnosis and are discovered incidentally. Clinical manifestations, when present, are influenced by the tumor site and by the time course over which it develops. Meningiomas are divided into three grades. Grade I represents the vast majority of cases; they are considered typical or benign, although their CNS location can still lead to severe morbidity or mortality, resulting in a reported ten-year net survival of over 80%. Atypical (WHO grade II) meningiomas are considered "intermediate grade" malignancies and represent 5-7% of cases. They show a tendency for recurrence and malignant degeneration with a relevant increase in tumor cell migration and surrounding tissue infiltration; ten-year net survival is reported over 60%. The anaplastic subtype (WHO III) represents only 1-3% of cases, and it is characterized by a poor prognosis (ten-year net survival of 15%). The treatment of choice for these tumors stands on complete microsurgical resection in case the subsequent morbidities are assumed minimal. On the other hand, and in case the tumor is located in critical regions such as the skull base, or the patient may have accompanied comorbidities, or it is aimed to avoid intensive treatment, some other approaches, including stereotactic radiosurgery and radiotherapy, were recommended as safe and effective choices to be considered as a primary treatment option or complementary to surgery. Adjuvant radiosurgery/radiotherapy should be considered in the case of atypical and anaplastic histology, especially when a residual tumor is identifiable in postoperative imaging. A "watchful waiting" strategy appears reasonable for extremely old individuals and those with substantial comorbidities or low-performance status, while there is a reduced threshold for therapeutic intervention for relatively healthy younger individuals due to the expectation that tumor progression will inevitably necessitate proactive treatment. To treat and manage meningioma efficiently, the assessments of both neurosurgeons and radiation oncologists are essential. The possibility of other rarer tumors, including hemangiopericytomas, solitary fibrous tumors, lymphomas, metastases, melanocytic tumors, and fibrous histiocytoma, must be considered when a meningeal lesion is diagnosed, especially because the ideal diagnostic and therapeutic approaches might differ significantly in every tumor type.

The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges

Associations of pathological diagnosis and genetic abnormalities in meningiomas with the embryological origins of the meninges

Spatial genomic, biochemical and cellular mechanisms underlying meningioma heterogeneity and evolution

Meningioma: current updates on genetics, classification, and mouse modeling

Spatial Distribution of Meningiomas: A Magnetic Resonance Image Atlas

Epidemiology, Genetics, and DNA Methylation Grouping of Hyperostotic Meningiomas

Meninges: A Widespread Niche of Neural Progenitors for the Brain

Meningioma and Other Meningeal Tumors

Pediatric meningiomas: A literature review and diagnostic update

The Molecular and Immunological Landscape of Meningiomas

Related mechanisms, current treatments, and new perspectives in meningioma

Epid-09. The Natural History And Molecular Architecture Of Incidental Meningiomas

Cancer stem cells in meningiomas: novel insights and therapeutic implications

Correlations Between Genomic Subgroup and Clinical Features in a Cohort of More Than 3000 Meningiomas.

Biom-22. Spatial, Single-Cell, And Bulk Rna Sequencing Identify Molecular Programs Underlying Meningioma Brain Invasion

Current immunotherapy techniques in meningioma

378 Meningiomas Causing Bony Hyperostosis Upregulate Cell Adhesion, Bone Mineralization, and Bone Development Gene Signatures

MicroRNAs in meningiomas: Potential biomarkers and therapeutic targets

The Evolving Classification of Meningiomas: Integration of Molecular Discoveries to Inform Patient Care

Somatic Mutation Landscape of a Meningioma and Its Pulmonary Metastasis

Genetic characterization and mutational profiling of foramen magnum meningiomas: a multi-institutional study